Famotidine
Brand names: Pepcid, Famotidine
At a glance
- Medicare prescriptions, 2024
- 12,849,675
- Medicare drug cost
- $165.7M
- Average cost per prescription
- $12.89
- Clinicians who prescribed it
- 215,803
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
PEPCID tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy.
From the FDA-approved prescribing information (label dated May 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Family Medicine 28.1%
- Internal Medicine 24.3%
- Nurse Practitioners 18.8%
- Gastroenterology 7.3%
- Physician Assistants 6.7%
- General Practice 4.2%
- ENT (Otolaryngology) 1.8%
- Geriatric Medicine 1.5%
- Nephrology (Kidney) 1.0%
- Pulmonology 0.8%
- Cardiology 0.7%
- Hospitalist 0.5%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 132% from 2019 to 2024.
Biggest change by state since 2019
- West Virginia +345%
- Delaware +311%
- Utah +290%
- Rhode Island +249%
- Maryland +247%
- California (smallest change) +62%
- Georgia (smallest change) +75%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Bausch Health US LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 20 mg | white round tablet, 7 mm | MP973 |
| 40 mg | white round tablet, 7 mm | MP974 |
Jones Healthcare Group - PAckaging Services, Inc
| Strength | Looks like | Imprint |
|---|---|---|
| 10 mg / 800 mg calcium carbonate / 165 mg magnesium hydroxide | purple round tablet, 18 mm | P |
Nucare Pharmaceutical, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | brown round tablet, 8 mm | L114 40 |
Pd-Rx Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 40 mg | white round tablet, 8 mm | T 12 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
5 recalls since 2020
- Aug 2026 · Baxter Healthcare Corporation · Class II
CGMP Deviations - Nov 2025 · Fresenius Kabi USA, LLC · Class I
Microbial Contamination of Sterile Products; out of limit results obtained for endotoxin testing. - Apr 2023 · Glenmark Therapeutics, Inc. · Class II
Labeling: Label Error on Declared Strength: some cartons labeled and containing 20 mg may have an external label placed on the side of the carton indicating strength as 10 mg. - Jan 2021 · Aurobindo Pharma USA Inc. · Class II
Presence of foreign tablets/capsules: Famotidine 20mg and ibuprofen 400mg tablets were found in a lot of famotidine 40mg. - Jun 2020 · Hf Acquisition Co. LLC · Class III
TEMPERATURE ABUSE: Complaint received from customer that product was received in a non-refrigerated state.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.